Adipotide (also known as FTPP or Prohibitin-TP01) is a first-in-class peptidomimetic developed by Arrowhead Research Corporation and MD Anderson Cancer Center. It comprises two functional domains:
- CKGGRAKDC – a homing motif that selectively binds prohibitin on the surface of white-fat blood-vessel endothelium
- D(KLAKLAK)₂ – a cationic, amphipathic proapoptotic sequence that disrupts mitochondrial membranes
After binding prohibitin, Adipotide is internalized and triggers rapid apoptosis of white-adipose vasculature, resulting in profound fat loss (up to 30% body weight in 28 days in obese rhesus monkeys). Originally advanced to Phase I for cancer-related cachexia, development was halted due to renal toxicity concerns at high doses. This research-grade lyophilized peptide is synthesized under strict quality controls and provided with full analytical documentation, making it the benchmark tool for selective adipocyte ablation and obesity research.
Key Scientific Features
- High-purity Adipotide (≥ 98% by HPLC/MS, TFA salt form)
- Verified dual-domain sequence: CKGGRAKDC-GG-D(KLAKLAK)₂ (cyclic via disulfide)
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, and amino acid analysis
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for prohibitin targeting, adipose vasculature apoptosis, and rapid fat-loss models
Research-Referenced Attributes (Based on scientific literature; not intended as therapeutic claims.)
- Selective apoptosis of white-fat endothelium → 30% body weight loss in 28 days (obese monkeys)
- 70–90% reduction in abdominal fat volume with minimal muscle loss
- Improves insulin sensitivity and reverses type 2 diabetes markers in preclinical models
- No effect on lean tissue vasculature (spares brown fat, muscle, organs)
- Rapid onset (weight loss visible within 7–10 days)
- Valuable in extreme obesity, metabolic syndrome, and cancer-cachexia research
Why Researchers Choose Nationwide Peptides Adipotide
- Exact clinical-sequence match used in original MD Anderson / Arrowhead studies
- Highest documented fat-specific apoptosis potency among research suppliers
- Transparent analytical data (HPLC >98%, MS confirmation of both domains)
- Trusted by obesity, vascular biology, and oncology laboratories
- Competitive research pricing with 5 mg, 10 mg, and bulk options
Disclaimer This product is intended strictly for laboratory research use only. Not for human consumption, injection, therapeutic application, or diagnostic procedures. For use by qualified researchers in controlled experimental settings only.
